Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — H1 2023 Earnings Presentation
23 slides from Marinomed Biotech's earnings presentation, Aug 17, 2023
Slide 1: Investor Presentation H1 2023
Investor Presentation H1 2023 Andreas Grassauer, CEO, Pascal Schmidt, CFO 17th August 2023
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Agenda
Agenda • Highlights year-to-date 2023 Andreas Grassauer, CEO • Financials H1 2023 Pascal Schmidt, CFO • Growth strategy Andreas Grassauer, CEO • Project outlook • Financial calendar, contact © Marinomed Biotech AG 3
Slide 4: Highlights year-to-date 2023
Highlights year-to-date 2023 Progress and new developments EUR 5.2 m Market Solv4U New product revenues authorization Partnership Strong H1 Carragelose eye For Carragelose With SPH Sine Carragelose drops – launch nasal spray in Pharmaceutical revenues planned for 2024 Mexico Laboratories © Marinomed
Slide 5: Agenda
Agenda • Highlights year-to-date 2023 Andreas Grassauer, CEO • Financials H1 2023 Pascal Schmidt, CFO • Growth strategy Andreas Grassauer, CEO • Project outlook • Financial calendar, contact © Marinomed Biotech AG 5
Slide 6: Record H1 revenues
Record H1 revenues Carragelose strong in H1 with post-pandemic slow-down of customer orders Development of half-yearly revenues (m€) Comments Historical numbers • Revenues rose from €4.9m to €5.2m (+7%) 2,1* • EBIT slightly decreased from €2.5m to €2.9m due to higher R&D expenses 5,8 6,3 6,4 4,9 5,2
Slide 7: Statement of profit or loss (IFRS)
Statement of profit or loss (IFRS) Higher revenues – increased R&D expenses €m H1 2023 H1 2022 1 H1 2023 H1 2022 Sale of goods 4.5 4.6 Revenues 1 5.2 4.9 Cost of goods sold -3.2 -3.1 Other income 2 0.3 0.5 Margin 28.0% 32.5% Materials expenses -3.3 -3.2 •2 Primarily consisting of research premium an
Slide 8: Statement of financial position (IFRS)
Statement of financial position (IFRS) Assets €m H1 2023 FY 2022 •1 Includes fully recognized headquarter, incl. land and building (€5.4m), therein directly R&D related* (€0.5m) Assets Intangible assets 1.7 1.8 2 Inventories €m H1 2023 FY 2022 Property, plant and equipment 1 6.1 6.2 Goods for sale 0
Slide 9: Statement of financial position (IFRS)
Statement of financial position (IFRS) Equity and liabilities €m H1 2023 FY 2022 •1 Primarily related to EIB loan (€15.0m) and ERP/aws and NÖBEG real estate refinancing (€4.8m) Equity and liabilities Share capital 1.5 1.5 Majority of accrued interest payable at maturity of loans. Capital reserves 44
Slide 10: Cash visibility into 2024
Cash visibility into 2024 Carragelose revenues reducing cash burn, repayment of loans ongoing •1 Operations mainly consisting of personnel costs and R&D expenses; MDR switch temporarily also contributing 1 1 2• Strong quarters in terms of Carragelose revenue contributing 1 significantly to reducing
Slide 11: Agenda
Agenda • Highlights year-to-date 2023 Andreas Grassauer, CEO • Financials H1 2023 Pascal Schmidt, CFO • Growth strategy Andreas Grassauer, CEO • Project outlook • Financial calendar, contact © Marinomed Biotech AG 11
Slide 12: Therapeutic Areas
Therapeutic Areas Proven track record with clinically validated and patent-protected technologies VIROLOGY IMMUNOLOGY • Carragelose from red seaweed: protective • Marinosolv technology: solubilization for layer with multi-use potential hydrophobic compounds • Clinically validated broad-spectrum viru
Slide 13: Marinomed strategic priorities
Marinomed strategic priorities Focus on revenue generation with existing products and product candidates INHALEEN • Long-term adherence to our mission MAM-1004-2 • Funding promising pipeline programs through own cash flows NEW ASSETS FOR ADDITIONAL GROWTH TACROSOLV BUDESOLV • Expanding business with
Slide 14: Pipeline
Pipeline Late-stage projects with low risk and high upside potential © Marinomed Biotech AG 14
Slide 15: Carragelose – growth strategy
Carragelose – growth strategy Expansion of territory, indication and product portfolio Target Action item Status / next steps USA → FDA registration USA (Procter & Gamble), Mexico and Territory expansion - registration Mexico → received market approval Brazil (M81) Brazil → ANVISA registration Conti
Slide 16: Carragelose Market comparison
Carragelose Market comparison The Mexican market for Cough, Cold & Allergy products is big and growing fast Mexico United Kingdom Germany • Population: 127.5mn • Population: 67.6mn • Population: 83.3mn • CHC1 sales per capita: USD 22.1 • CHC sales per capita: USD 42.9 • CHC sales per capita: USD 66.
Slide 17: Carragelose
Carragelose Lubricating and protective layer against viruses and pollen – multi-use potential Viral respiratory diseases Carragelose – extracted from red Eye care • Broadly-active against several seaweed • Carragelose has excellent respiratory viruses lubricating properties Forms a protective • Clin
Slide 18: Immunology – focus on business development
Immunology – focus on business development Expansion of territory, indication and product portfolio Area / Product Action item Status / next steps Complete the BD process and enable Tacrosolv (MAM-1003-1) Run a structured BD process with a partnership within the next 6-12 Inflammatory eye diseases e
Slide 19: Solv4U Partnership with SPH Sine
Solv4U Partnership with SPH Sine Long-term partnership with high future potential • License to use Marinosolv technology • Provides Marinosolv technology • Worldwide rights for one undisclosed drug candidate • Maintains the IP and assists in creating new IP • Covers all future development costs • Su
Slide 20: Outlook
Outlook Continue strategy with focus on near-term revenues • Strong H1, H2 2023 Carragelose revenues impacted by post- pandemic effects Strengthen existing business • Drive Carragelose in the U.S., Mexico and others and partnerships to ensure • Launch Carragelose allergy and eye products in 2024 sus
Slide 21: Agenda
Agenda • Highlights year-to-date 2023 Andreas Grassauer, CEO • Financials H1 2023 Pascal Schmidt, CFO • Growth strategy Andreas Grassauer, CEO • Project outlook • Financial calendar, contact © Marinomed Biotech AG 21
Slide 22: Financial calendar & IR contact
Financial calendar & IR contact Financial Calendar 2023 November 21, 2023 Publication of the Results Q1-3 2023 Stephanie Kniep Investor Relations phone: +43 2262 90300 226 e-mail: IR@marinomed.com © Marinomed Biotech AG 22
Slide 23: www.marinomed.com
www.marinomed.com 0) Marinomed